Personalized Medicine in Psychiatry最新文献

{"title":"Randomized, Placebo-controlled, Antidepressant Treatment of Patients with Major Depressive Disorder: Changes in Glomerular Filtration Rate","authors":"Melissa Claros-Erazo ,&nbsp;Hua Li ,&nbsp;Ivonne H. Schulman ,&nbsp;Dominique L. Musselman","doi":"10.1016/j.pmip.2021.100083","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100083","url":null,"abstract":"<div><h3>Background</h3><p><span>A bidirectional relationship between depression and renal dysfunction has been posited, however, a paucity of longitudinal data exists in individuals with major depression disorder (MDD). As depression may contribute to the progression of </span>chronic kidney disease<span><span> (CKD), we sought to determine whether effective depression treatment was associated with improvement in </span>renal function.</span></p></div><div><h3>Methods</h3><p>A retrospective analysis performed on 1600 outpatients who underwent double-blind, placebo-controlled, randomized antidepressant treatment (DBPCRAT) of MDD in thirteen Eli Lilly and Company clinical trials<span>. Magnitude of depression symptoms was measured with the Hamilton Depression Rating scale<span> (HAMD); glomerular filtration rate (eGFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.</span></span></p></div><div><h3>Results</h3><p><span>After 7 weeks of DBPCRAT, HAMD scores in the treatment group decreased by 11.8 points, compared to 9.3 points in the placebo group (p &lt; 0.0001). In the antidepressant-treated group, eGFR decreased by 0.28 ml/min/1.73 m</span>² and by 0.88 ml/min/1.73 m² in the placebo-treated group (p = 0.17). Predictors of HAMD score at week 7 were baseline HAMD score (B = 0.237; p &lt; 0.001), and antidepressant treatment (B = −2.28, p &lt; 0.001). Predictors of eGFR were baseline eGFR (B = 0.651, p &lt; 0.0001), increasing age (B = −0.194, p &lt; 0.0001), and female gender (B = −0.984, p = 0.013).</p></div><div><h3>Conclusion</h3><p>Short-term, MDD was not associated with clinically significant decrements in eGFR. Future studies will determine whether depression treatment over a more prolonged period of time is associated with improvement in eGFR, especially in minorities and other high-risk populations.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100083"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92130493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion in bipolar disorder: Impact of COVID-19 on outcomes and treatment of bipolar disorder","authors":"David Spelber,&nbsp;Stephen M. Strakowski","doi":"10.1016/j.pmip.2021.100074","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100074","url":null,"abstract":"<div><p>Bipolar disorder<span> is a common mental illness with a high burden of disability and comorbidity including highly prevalent medical conditions that increase risk for severe COVID-19 illness. Moreover, increased vulnerability to stress, routine and lifestyle disruption in people living with bipolar disorder is well-established. Although data examining the impact of COVID-19 disease and the resulting pandemic on those with bipolar disorder are limited, the present paper aims to discuss existing research at the intersection of COVID-19 and mental health with the goal of considering potential impacts of COVID-19 on outcomes and treatment of bipolar disorder.</span></p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100074"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100074","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91998417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion in psychotherapy: The transformation of psychotherapy practice in the Covid-19 era","authors":"Glen O. Gabbard","doi":"10.1016/j.pmip.2021.100075","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100075","url":null,"abstract":"","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100075"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91985930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion in panic disorder: The impact of COVID-19-related fears, protective devices, and lockdown on panic and agoraphobia","authors":"Daniela Caldirola ,&nbsp;Silvia Daccò ,&nbsp;Francesco Cuniberti ,&nbsp;Giampaolo Perna","doi":"10.1016/j.pmip.2021.100080","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100080","url":null,"abstract":"<div><p><span>During the COVID-19 pandemic a perceived decline of mental well-being was reported both in people with preexisting psychiatric disorders and in people without. However, individuals with different psychiatric vulnerabilities may differ in their responses to COVID-19-related stressors. In this commentary we proposed a few considerations on possible peculiar patterns of pandemic-related behaviors or complaints </span>in patients<span> suffering from panic disorder (PD) with or without agoraphobia (AG). Individuals with PD may be particularly sensitive to multiple pandemic-related aspects involving respiration (e.g., wearing facial masks or COVID-19-related respiratory symptoms) that may worsen or trigger panic symptoms. In case of comorbid AG, an initial improvement of panic–phobic symptoms during the lockdown may have occurred, followed by a subsequent symptom exacerbation when the containment measures became less rigorous, possibly related to lockdown-associated negative reinforcement and impairment in consolidation of fear extinction. Personalized interventions should be offered to the patients to minimize the risk of worsening or relapse.</span></p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100080"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91998418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion in obsessive-compulsive disorder: Treating patients with obsessive-compulsive disorder during the COVID-19 pandemic","authors":"Abigail E. Candelari ,&nbsp;Katharine D. Wojcik ,&nbsp;Andrew D. Wiese ,&nbsp;Wayne K. Goodman ,&nbsp;Eric A. Storch","doi":"10.1016/j.pmip.2021.100079","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100079","url":null,"abstract":"<div><p><span><span>This commentary outlines assessment and treatment of patients with </span>OCD during the era of COVID-19. The ongoing COVID-19 pandemic has required providers to make important considerations in treatment, including how </span><em>usual risk</em><span> is defined, as well as the use of personal protective equipment<span> and telehealth services. These considerations have allowed providers to continue using both reliable and valid assessment procedures, as well as previously established and efficacious interventions. These adjustments create a context in which patient care for OCD remains fundamentally unchanged; however, important considerations should still be made because of the COVID-19 pandemic.</span></span></p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100079"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92124840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health","authors":"Giampaolo Perna ,&nbsp;Francesco Cuniberti ,&nbsp;Charles B. Nemeroff","doi":"10.1016/j.pmip.2021.100077","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100077","url":null,"abstract":"","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100077"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91998420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion in Obsessive-Compulsive Disorder: Could protective measures for COVID-19 contribute to the worsening of OCD symptoms?","authors":"Samantha Baldi,&nbsp;Koen Schruers","doi":"10.1016/j.pmip.2021.100076","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100076","url":null,"abstract":"<div><p>The COVID-19 outbreak has placed considerable strain on the wellbeing of individuals across the world, and resources have been already put in place to assess the psycho-social aftermath of this pandemic. With strict hygiene measures and recommendations now constituting the norm, we wonder specifically about those individuals that were heavily concerned by contamination, germs and viruses in the pre-COVID era. Patients affected by obsessive–compulsive disorder (OCD), and specifically those of the contamination/washing subtype, might indeed be exceptionally vulnerable to an increase in symptom severity due to the current circumstances. Albeit only relating to the acute phase of this pandemic, evidence collected thus far offer valuable insights into whether this concern is substantiated. After reviewing some of the available results, we reason on the conclusions that we can currently draw, on the factors that might play a role in driving them and on those that might be worth focusing on as the pandemic is running its course.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100076"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91998416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary insights into the genetic architecture of postpartum depressive symptom severity using polygenic risk scores","authors":"Jennie G. Pouget ,&nbsp;Valerie H. Taylor ,&nbsp;Cindy-Lee Dennis ,&nbsp;Sophie Grigoriadis ,&nbsp;The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Inflammation Working Group,&nbsp;Tim Oberlander ,&nbsp;Benicio N. Frey ,&nbsp;Ryan Van Lieshout ,&nbsp;Jerry Guintivano ,&nbsp;Samantha Meltzer-Brody ,&nbsp;James L. Kennedy ,&nbsp;Simone N. Vigod","doi":"10.1016/j.pmip.2021.100081","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100081","url":null,"abstract":"<div><h3>Background</h3><p>Genetic factors influence susceptibility to postpartum mood disorders (PPMDs). However, the genetic architecture of PPMDs remains poorly understood. This study explored the genetic architecture of depressive symptom severity in a transdiagnostic sample of Canadian women with self-report PPMDs.</p></div><div><h3>Methods</h3><p><span><span>Women with self-reported current or past postpartum depression<span> (PPD) or past postpartum psychosis<span> (PPP) were recruited online via social media from across Canada. Postpartum depressive symptom severity was measured by self-report using the Edinburgh Postnatal Depression Scale (EPDS) through an iPhone application that is part of a large international study. Polygenic risk scoring (PRS) was applied to evaluate the genetic relationship between EPDS score and six non-perinatal psychiatric disorders (anxiety, </span></span></span>bipolar disorder<span>, depression, neuroticism<span>, obsessive compulsive disorder<span>, schizophrenia) and three putative PPMD biomarkers (C reactive protein (CRP), thyroxine (T4), progesterone). Exploratory </span></span></span></span>Mendelian randomization was performed to evaluate causal relationships between biomarker levels and EPDS score.</p></div><div><h3>Results</h3><p>Polygenic risk scores for (1) bipolar disorder, (2) depression, and (3) serum CRP levels were positively associated with EPDS score among women with PPMDs (p &lt; 0.05 after multiple testing correction). Mendelian randomization did not suggest a causal relationship between CRP levels and EPDS scores, but lacked sufficient statistical power.</p></div><div><h3>Conclusions</h3><p>This transdiagnostic study provides preliminary insights into the genetic architecture of postpartum depressive symptom severity as a dimensional trait. Our findings suggest there are shared genetic risk factors for postpartum depressive symptom severity and susceptibility to mood disorders outside the perinatal window, and highlight the potential role of inflammation in influencing postpartum depressive symptom severity.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91998419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cooperative studies Program (CSP) #572: A study of serious mental illness in veterans as a pathway to personalized medicine in schizophrenia and bipolar illness","authors":"Philip D. Harvey ,&nbsp;Tim B. Bigdeli ,&nbsp;Ayman H. Fanous ,&nbsp;Yuli Li ,&nbsp;Nallakkandi Rajeevan ,&nbsp;Frederick Sayward ,&nbsp;Krishnan Radhakrishnan ,&nbsp;Grant Huang ,&nbsp;Mihaela Aslan","doi":"10.1016/j.pmip.2021.100078","DOIUrl":"10.1016/j.pmip.2021.100078","url":null,"abstract":"<div><h3>Background</h3><p><span><span>Personalization of psychiatric treatment<span> includes treatment of symptoms, cognition and functional deficits, suicide, and medical co-morbidities. </span></span>VA<span> Collaborative Study 572 examined a large sample of male and female veterans with schizophrenia (n = 3,942) and with </span></span>bipolar disorder (n = 5,414) with phenotyping and genomic analyses. We present the results to date and future directions.</p></div><div><h3>Methods</h3><p>All veterans received a structured diagnostic interview and assessments of suicidal ideation and behavior, PTSD<span>, and health. Veterans with schizophrenia were assessed for negative symptoms and lifetime depression. All were assessed with a cognitive and functional capacity assessment. Data for genome wide association studies were collected. Controls came from the VA Million Veteran Program.</span></p></div><div><h3>Results</h3><p>Suicidal ideation or behavior was present in 66%. Cognitive and functional deficits were consistent with previous studies. 40% of the veterans with schizophrenia had a lifetime major depressive episode and PTSD was present in over 30%. Polygenic risk score (PRS) analyses indicated that cognitive and functional deficits overlapped with PRS for cognition, education, and intelligence in the general population and PRS for suicidal ideation and behavior correlated with previous PRS for depression and suicidal ideation and behavior, as did the PRS for PTSD.</p></div><div><h3>Discussion</h3><p>Results to date provide directions for personalization of treatment in SMI, veterans with SMI, and veterans in general. The results of the genomic analyses suggest that cognitive deficits in SMI may be associated with general population features. Upcoming genomic analyses will reexamine the issues above, as well as genomic factors associated with smoking, substance abuse, negative symptoms, and treatment response.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"27 ","pages":"Article 100078"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39152213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion in anxiety disorder: Corona-phobia, the new face of anxiety","authors":"Antonio E. Nardi ,&nbsp;Fiammetta Cosci","doi":"10.1016/j.pmip.2021.100070","DOIUrl":"https://doi.org/10.1016/j.pmip.2021.100070","url":null,"abstract":"<div><p>The Covid-19 pandemic changed our lives quickly and abruptly. This occurred in a radical and, often, unexpected way. During 2020, in favor of social distance, restrictions on leaving home, participating in social activities, and even working impacted our lives. The health agenda in the face of the pandemic encompasses a huge range of areas that must be covered, but it is necessary to draw the attention to the general population mental health, which gives worrying evidence. The pandemic has been described by epidemiologists in terms of waves of infection. The world is now facing the second wave of infection and the experts already worry for the third one. However, another wave has occurred in between and within the waves of infection; it is the wave of mental health problems caused directly by the infection or by its secondary consequences.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"25 ","pages":"Article 100070"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92073279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}